CN112262212B - 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 - Google Patents

使用羟基柠檬酸和/或其盐产生t细胞群体的方法 Download PDF

Info

Publication number
CN112262212B
CN112262212B CN201980037634.5A CN201980037634A CN112262212B CN 112262212 B CN112262212 B CN 112262212B CN 201980037634 A CN201980037634 A CN 201980037634A CN 112262212 B CN112262212 B CN 112262212B
Authority
CN
China
Prior art keywords
cells
hydroxycitrate
salt
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980037634.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112262212A (zh
Inventor
苏曼·库玛·沃德纳拉
尼古拉斯·P·雷斯蒂福
里吉尔·J·基斯顿
罗伯特·L·艾尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Priority to CN202410809055.0A priority Critical patent/CN118726256A/zh
Publication of CN112262212A publication Critical patent/CN112262212A/zh
Application granted granted Critical
Publication of CN112262212B publication Critical patent/CN112262212B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN201980037634.5A 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 Active CN112262212B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410809055.0A CN118726256A (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661941P 2018-04-24 2018-04-24
US62/661,941 2018-04-24
PCT/US2019/028513 WO2019209715A1 (en) 2018-04-24 2019-04-22 Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410809055.0A Division CN118726256A (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法

Publications (2)

Publication Number Publication Date
CN112262212A CN112262212A (zh) 2021-01-22
CN112262212B true CN112262212B (zh) 2024-07-12

Family

ID=66641471

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980037634.5A Active CN112262212B (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
CN202410809055.0A Pending CN118726256A (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410809055.0A Pending CN118726256A (zh) 2018-04-24 2019-04-22 使用羟基柠檬酸和/或其盐产生t细胞群体的方法

Country Status (7)

Country Link
US (2) US12415845B2 (enExample)
EP (1) EP3784774B1 (enExample)
JP (1) JP7342030B2 (enExample)
CN (2) CN112262212B (enExample)
AU (1) AU2019260656B2 (enExample)
CA (1) CA3097858A1 (enExample)
WO (1) WO2019209715A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3959305A1 (en) * 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
WO2021222479A1 (en) * 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
EP4178590A4 (en) * 2020-07-09 2024-09-25 The Board of Trustees of the Leland Stanford Junior University MULTIPARALLEL ANALYSIS OF T-CELL THERAPIES

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
US9345748B2 (en) 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
ES2835200T3 (es) 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
US9879065B2 (en) 2012-09-14 2018-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing MHC class II-restricted MAGE-A3
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
CA2936984A1 (en) 2014-01-24 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
ES2924709T3 (es) 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
US20170312200A1 (en) * 2014-10-29 2017-11-02 Showa Denko K.K. An agent for improving mitochondrial function
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
US20190321314A1 (en) 2016-09-15 2019-10-24 Memorial Sloan Kettering Cancer Center Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Adoptive T cell therapy using antigen-specific CD8 T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells;C. Yee等;PNAS;第99卷(第25期);参见对比文件1摘要、材料和方法 *

Also Published As

Publication number Publication date
EP3784774C0 (en) 2025-11-19
JP2021521828A (ja) 2021-08-30
CN112262212A (zh) 2021-01-22
AU2019260656A1 (en) 2020-12-10
JP7342030B2 (ja) 2023-09-11
CA3097858A1 (en) 2019-10-31
CN118726256A (zh) 2024-10-01
US20260042814A1 (en) 2026-02-12
US20210071141A1 (en) 2021-03-11
WO2019209715A1 (en) 2019-10-31
AU2019260656B2 (en) 2025-08-21
US12415845B2 (en) 2025-09-16
EP3784774A1 (en) 2021-03-03
AU2019260656A2 (en) 2020-12-17
EP3784774B1 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
US11123369B2 (en) Bispecific CAR T-cells for solid tumor targeting
US11896616B2 (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP6203705B2 (ja) 細胞免疫療法のための方法および組成物
US20260042814A1 (en) Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
TW202500743A (zh) 表現免疫機能控制因子之免疫活性細胞及表現載體
JP7747724B2 (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
JP2017531640A (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
CN108473956A (zh) 增强外源性施用t细胞的体内持久性和功效的方法、基因修饰的t细胞和方法以及使用方法
TW202102667A (zh) 用於擴增和分化供過繼性細胞治療之ｔ淋巴細胞和天然殺手（ｎｋ）細胞之方法
CN117295515A (zh) 用于癌症免疫治疗的嵌合抗原受体修饰的粒细胞-巨噬细胞祖细胞
US20230036952A1 (en) Methods of producing t cell populations using induced pluripotent stem cells
US20220152108A1 (en) Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor
US20250228939A1 (en) Enhanced immune cell therapy
Di Trani Tailoring the bioactivities of IL-12 for cancer immunotherapy with mRNA-based technology: from immunocytokines to armored T cell transfer
Cimons The Impact of Lineage-Specifying Transcription Factor Overexpression on Car T Cell Function
WO2025054946A1 (zh) 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
WO2021211663A1 (en) Chimeric myd88 receptors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant